This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Title VII of the Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111–48, Improving Access to Innovative Medical Therapies—Subtitle (2010).
Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nature Rev. Drug Discov. 7, 479–488 (2008).
Federal Trade Commission (FTC). Emerging Health Care Issues: Follow-on Biologic Drug Competition. Federal Trade Commission Report | June 2009. FTC website [online], (2009).
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Grabowski, H., Long, G. & Mortimer, R. Data exclusivity for biologics. Nat Rev Drug Discov 10, 15–16 (2011). https://doi.org/10.1038/nrd3277
This article is cited by
Erratum: Data exclusivity for biologics
Nature Reviews Drug Discovery (2011)